, Volume 233, Issue 23–24, pp 3891–3903 | Cite as

Adolescent d-amphetamine treatment in a rodent model of attention deficit/hyperactivity disorder: impact on cocaine abuse vulnerability in adulthood

  • Chloe J. Jordan
  • Carley Lemay
  • Linda P. Dwoskin
  • Kathleen M. KantakEmail author
Original Investigation



Stimulant medications for attention-deficit/hyperactivity disorder (ADHD) in adolescents remain controversial with respect to later development of cocaine abuse. Past research demonstrated that adolescent methylphenidate treatment increased several aspects of cocaine self-administration during adulthood using the spontaneously hypertensive rat (SHR) model of ADHD. Presently, we determined effects of the alternate stimulant medication, d-amphetamine, on cocaine self-administration.


We tested the hypothesis that adolescent d-amphetamine would not increase cocaine self-administration in adult SHR, given that d-amphetamine has a different mechanism of action than methylphenidate.


A pharmacologically relevant dose of d-amphetamine (0.5 mg/kg) or vehicle was administered throughout adolescence to SHR and two control strains, Wistar-Kyoto (WKY) and Wistar (WIS). Three aspects of cocaine abuse vulnerability were assessed in adulthood after discontinuing adolescent treatments: acquisition rate and dose-related responding under fixed (FR) and progressive (PR) ratio schedules.


Adult SHR acquired cocaine self-administration faster and self-administered more cocaine across multiple doses compared to WKY and WIS under FR and PR schedules, indicating that SHR is a reliable animal model of comorbid ADHD and cocaine abuse. Relative to vehicle, SHR and WIS with adolescent d-amphetamine treatment self-administered less cocaine upon reaching acquisition criteria, and WIS additionally acquired cocaine self-administration more slowly and had downward shifts in FR and PR cocaine dose-response curves. WKY with adolescent d-amphetamine treatment acquired cocaine self-administration more quickly relative to vehicle.


In contrast to methylphenidate, adolescent d-amphetamine did not augment cocaine self-administration in SHR. Adolescent d-amphetamine treatment actually protected against cocaine abuse vulnerability in adult SHR and WIS.


Adolescence Attention deficit/hyperactivity disorder Cocaine self-administration d-Amphetamine Spontaneously hypertensive rat 



The authors thank Laura Tabbaa, Sae-Mi Jeon, and Britahny Baskin for research assistance.


National Institutes of Health grant DA011716 and the Clara Mayo Memorial Fellowship at Boston University.

Conflict of interest

Chloe Jordan, Carley Lemay, Linda Dwoskin, and Kathleen Kantak declare no conflicts of interest.

Research involving animals

All procedures were approved by the Boston University Institutional Animal Care and Use Committee and were in accordance with the National Institutes of Health Guide For the Care and Use of Laboratory Animals (8th Edition).


  1. Adriani W, Caprioli A, Granstrem O, Carli M, Laviola G (2003) The spontaneously hypertensive-rat as an animal model of ADHD: evidence for impulsive and non-impulsive subpopulations. Neurosci Biobehav Rev 27:639–651CrossRefPubMedGoogle Scholar
  2. Arnold LE, Kirilcuk V, Corson SA, Corson EOL (1973) Levoamphetamine and dextroamphetamine: differential effect on aggression and hyperkinesis in children and dogs. Am J Psychiatry 130:165–170CrossRefPubMedGoogle Scholar
  3. Baskin BM, Dwoskin LP, Kantak KM (2015) Methylphenidate treatment beyond adolescence maintains increased cocaine self-administration in the spontaneously hypertensive rat model of attention deficit/hyperactivity disorder. Pharm. Biochem Behav 131:51–56CrossRefGoogle Scholar
  4. Bayless DW, Perez MC, Daniel JM (2015) Comparison of the validity of the use of the spontaneously hypertensive rat as a model of attention deficit hyperactivity disorder in males and females. Behav Brain Res 286:85–92CrossRefPubMedGoogle Scholar
  5. Beránková K, Szkutová M, Balíková M (2007) Distribution profile of 2,5-dimethoxy-4-bromoamphetamine (DOB) in rats after oral and subcutaneous doses. Forensic Sci Int 170:94–99CrossRefPubMedGoogle Scholar
  6. Berger DF, Sagvolden T (1998) Sex differences in operant discrimination behaviour in an animal model of attention-deficit hyperactivity disorder. Behav Brain Res 94:73–82CrossRefPubMedGoogle Scholar
  7. Brown GL, Hunt RD, Ebert MH, Bunney WE Jr, Kopin IJ (1979) Plasma levels of d- amphetamine in hyperactive children: serial behavior and motor responses. Psychopharmacology 62:133–140CrossRefPubMedGoogle Scholar
  8. Bymaster FP, Katner JS, Nelson DL, Hemrick-Luecke SK, Threlkeld PG, Heiligenstein JH, et al. (2002) Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/hyperactivity disorder. Neuropsychopharmacology 27:699–711CrossRefPubMedGoogle Scholar
  9. Caihol S, Mormède P (1999) Strain and sex differences in the locomotor response and behavioral sensitization to cocaine in hyperactive rats. Brain Res 842:200–205CrossRefGoogle Scholar
  10. Chiodo KA, Läck CM, Roberts DC (2008) Cocaine self-administration reinforced on a progressive ratio schedule decreases with continuous D-amphetamine treatment in rats. Psychopharmacology 200:465–473CrossRefPubMedPubMedCentralGoogle Scholar
  11. Cohen J (1988) Statistical power analysis for the behavioral sciences, 2nd edn. Erlbaum, Hillsdale, NJGoogle Scholar
  12. Crunelle CL, van den Brink W, Veltman DJ, van Emmerik-van Oortmerssen K, Dom G, Schoevers RA, Booij J (2013) Low dopamine transporter occupancy by methylphenidate as a possible reason for reduced treatment effectiveness in ADHD patients with cocaine dependence. Eur Neuropsychopharm 23:1714–1723CrossRefGoogle Scholar
  13. Cubillo A, Halari R, Giampietro V, Taylor E, Rubia K (2011) Fronto-striatal underactivation during interference inhibition and attention allocation in grown up children with attention deficit/hyperactivity disorder and persistent symptoms. Psychiatr Res 193:17–27CrossRefGoogle Scholar
  14. Czoty PW, Martelle JL, Nader MA (2010) Effects of chronic d-amphetamine administration on the reinforcing strength of cocaine in rhesus monkeys. Psychopharm (Berl) 209:375–382CrossRefGoogle Scholar
  15. Dalsgaard S, Mortensen PB, Frydenberg M, Thomsen PH (2014) ADHD, stimulant treatment in childhood and subsequent substance abuse in adulthood - a naturalistic long- term follow-up study. Addict Behav 39:325–328CrossRefPubMedGoogle Scholar
  16. De La Garza R II, Mahoney JJ III (2004) A distinct neurochemical profile in WKY rats at baseline and in response to acute stress: implications for animal models of anxiety and depression. Brain Res 1021:209–218CrossRefPubMedGoogle Scholar
  17. Ferguson SA, Cada AM (2003) A longitudinal study of short- and long-term activity levels in male and female spontaneously hypertensive, Wistar-Kyoto, and Sprague-Dawley rats. Behav Neurosci 117:271–282CrossRefPubMedGoogle Scholar
  18. Ferris MJ, Calipari ES, Rose JH, Siciliano CA, Sun H, Chen R, Jones SR (2015) A single amphetamine infusion reverses deficits in dopamine nerve-terminal function caused by a history of cocaine self-administration. Neuropsychopharmacology 40:1826–1836CrossRefPubMedPubMedCentralGoogle Scholar
  19. Grabowski J, Rhoades H, Schmitz J, Stotts A, Daruzska LA, Creson D, Moeller FG (2001) Dextroamphetamine for cocaine-dependence treatment: a double-blind randomized clinical trial. J Clin Psychopharm 21:522–526CrossRefGoogle Scholar
  20. Grace AA (2001) Psychostimulant actions on dopamine and limbic system function: relevance to the pathophysiology and treatment of ADHD. In: Solanto MV, Arnsten AFT, Castellanos FX (eds) Stimulant drugs and ADHD: basic and clinical neuroscience. Oxford University Press, London, United Kingdom, pp. 134–157Google Scholar
  21. Harvey RC, Sen S, Deaciuc A, Dwoskin LP, Kantak KM (2011) Methylphenidate treatment in adolescent rats with an attention deficit/hyperactivity disorder phenotype: cocaine addiction vulnerability and dopamine transporter function. Neuropsychopharmacology 36:837–847CrossRefPubMedGoogle Scholar
  22. Heal DJ, Smith SL, Gosden J, Nutt DJ (2013) Amphetamine, past and present - a pharmacological and clinical perspective. J Psychopharm 27:479–496CrossRefGoogle Scholar
  23. Heijtz RD, Kolb B, Forssberg H (2003) Can a therapeutic dose of amphetamine during pre-adolescence modify the pattern of synaptic organization in the brain? European. J Neurosci 18:3394–3399Google Scholar
  24. Hester R, Garavan H (2004) Executive dysfunction in cocaine addiction: evidence for discordant frontal, cingulate, and cerebellar activity. J Neurosci 24:11017–11022CrossRefPubMedGoogle Scholar
  25. Hill JC, Herbst K, Sanabria F (2012) Characterizing operant hyperactivity in the spontaneously hypertensive rat. Behav Brain Func 8:5CrossRefGoogle Scholar
  26. Humphreys KL, Eng T, Lee SS (2013) Stimulant medication and substance use outcomes: a meta-analysis. JAMA Psychiatry 70:740–749CrossRefPubMedGoogle Scholar
  27. Jiao X, Pare WP, Tejani-Butt SM (2003) Strain differences in the distribution of dopamine transporter sites in rat brain. Prog Neuropsychopharm Biol Psychiatry 27:913–919CrossRefGoogle Scholar
  28. Jordan CJ, Harvey RC, Baskin BB, Dwoskin LP, Kantak KM (2014) Cocaine-seeking behavior in a genetic model of attention-deficit/hyperactivity disorder following adolescent methylphenidate or atomoxetine treatments. Drug Alcohol Depend 140:25–32CrossRefPubMedPubMedCentralGoogle Scholar
  29. Jordan CJ, Taylor DM, Dwoskin LP, Kantak KM (2016) Adolescent d-amphetamine treatment in a rodent model of ADHD: pro-cognitive effects in adolescence without an impact on cocaine cue reactivity in adulthood. Behav Brain Res 297:165–179CrossRefPubMedGoogle Scholar
  30. Konstenius M, Jayaram-Lindström N, Beck O, Franck J (2010) Sustained release methylphenidate for the treatment of ADHD in amphetamine abusers: a pilot study. Drug Alcohol Depend 108:130–133CrossRefPubMedGoogle Scholar
  31. Kuczenski R, Segal DS (2001) Locomotor effects of acute and repeated threshold doses of amphetamine and methylphenidate: Relative roles of dopamine and norepinephrine. J Pharmacol Exp Ther 296: 876–883Google Scholar
  32. Lambert NM, Hartsough CS (1998) Prospective study of tobacco smoking and substance dependencies among samples of ADHD and non-ADHD participants. J Learn Disabilities 31:533–544CrossRefGoogle Scholar
  33. Lee SS, Humphreys KL, Flory K, Liu R, Glass K (2011) Prospective association of childhood attention-deficit/hyperactivity disorder (ADHD) and substance use and abuse/dependence: a meta-analytic review. Clin Psych Rev 31:328–341CrossRefGoogle Scholar
  34. Levin, FR, Mariani, JJ, Specker, S, Mooney, M, Mahony, A, Brooks, DJ (2015) Extended-release mixed amphetamine salts vs placebo for comorbid adult attention-deficit/hyperactivity disorder and cocaine use disorder: a randomized clinical trial. JAMA Psychiatry 72:593–602Google Scholar
  35. Lindemann L, Meyer CA, Jeanneau K, Bradaia A, Ozmen L, Bluethmann H, Bettler B, et al. (2008) Trace amine-associated receptor 1 modulates dopaminergic activity. J Pharm Exper Therapeutics 324:948–956CrossRefGoogle Scholar
  36. Loh EA, Roberts DCS (1990) Break-points on a progressive ratio schedule reinforced by intravenous cocaine increase following depletion of forebrain serotonin. Psychopharmacology 101:262–266CrossRefPubMedGoogle Scholar
  37. Mannuzza S, Klein RG, Truong NL, Moulton JL, Roizen ER, Howell KH, et al. (2008) Age of methylphenidate treatment initiation in children with ADHD and later substance abuse: prospective follow-up into adulthood. Am Journal Psychiatry 165:604–609CrossRefGoogle Scholar
  38. Martins S, Tramontina S, Polanczyk G, Eizirik M, Swanson JM, Rohde LA (2004) Weekend holidays during methylphenidate use in ADHD children: a randomized clinical trial. J Child Adol Psychopharm 14:195–206CrossRefGoogle Scholar
  39. Miller GM (2011) The emerging role of trace amine-associated receptor 1 in the functional regulation of monoamine transporters and dopaminergic activity. J Neurochem 116:164–176CrossRefPubMedPubMedCentralGoogle Scholar
  40. Molina BS, Hinshaw SP, Eugene Arnold L, Swanson JM, Pelham WE, Hechtman L, Hoza B, Epstein JN, Wigal T, Abikoff HB, Greenhill LL, Jensen PS, Wells KC, Vitiello B, Gibbons RD, Howard A, Houck PR, Hur K, Lu B, Marcus S (2013) Adolescent substance use in the multimodal treatment study of attention-deficit/hyperactivity disorder (ADHD) (MTA) as a function of childhood ADHD, random assignment to childhood treatments, and subsequent medication. J Am Acad Child Adolesc Psychiatry 52:250–263CrossRefPubMedPubMedCentralGoogle Scholar
  41. Mooney ME, Herin DV, Schmitz JM, Moukaddam N, Green CE, Grabowski J (2009) Effects of oral methamphetamine on cocaine use: a randomized, double-blind, placebo- controlled trial. Drug Alcohol Depend 101:34–41CrossRefPubMedGoogle Scholar
  42. National Survey of Children's Health. NSCH 2011/12. Data query from the Child and Adolescent HealthMeasurement Initiative, Data Resource Center for Child and Adolescent Health website. Retrieved from Accessed 20 Mar 2016
  43. Negus SS (2003) Rapid assessment of choice between cocaine and food in rhesus monkeys: effects of environmental manipulations and treatment with d-amphetamine and flupenthixol. Neuropsychopharmacology 28:919–931PubMedGoogle Scholar
  44. Pardon M-C, Gould GG, Garcia A, Phillips L, Cook MC, Miller A, et al. (2002) Stress reactivity of the brain noradrenergic system in three rat strains differing in their neuroendocrine and behavioral responses to stress: implications for susceptibility to stress-related neuropsychiatric disorders. Neurosci 115:229–242CrossRefGoogle Scholar
  45. Paré W, Kluczynski J (1997) Differences in the stress response of Wistar-Kyoto (WKY) rats from different vendors. Physiol Behav 62:643–648CrossRefPubMedGoogle Scholar
  46. Patrick KS, Morowitz JS (1997) Pharmacology of methylphenidate, amphetamine enantiomers and pemoline in attention-deficit hyperactivity disorder. Human Psychopharm 12:527–546CrossRefGoogle Scholar
  47. Piazza PV, Deroche-Gamonent V, Rouge-Pont F, Le Moal M (2000) Vertical shifts in self-administration dose-response functions predict a drug-vulnerable phenotype predisposed to addiction. J Neurosci 20:4226–4232PubMedGoogle Scholar
  48. Richardson NR, Roberts DC (1996) Progressive ratio schedules in drug self-administration studies in rats: a method to evaluate reinforcing efficacy. J Neurosci Methods 66:1–11CrossRefPubMedGoogle Scholar
  49. Roessner V, Sagvolden T, DasBanerjee T, Middleton FA, Faraone SV, Walaas SI, et al. (2010) Methylphenidate normalizes elevated dopamine transporter densities in an animal model of the attention-deficit/hyperactivity disorder combined type, but not to the same extent in one of the attention-deficit/hyperactivity disorder inattentive type. Neurosci 167:1183–1191CrossRefGoogle Scholar
  50. Russell VA (2011) Overview of animal models of attention deficit hyperactivity disorder (ADHD). Curr Protoc Neurosci Chapter 9(Unit 9):35PubMedGoogle Scholar
  51. Sagvolden T (2000) Behavioral validation of the spontaneously hypertensive rat (SHR) as an animal model of attention-deficit/hyperactivity disorder (AD/HD). Neurosci Biobehav Rev 24:31–39CrossRefPubMedGoogle Scholar
  52. Scholl JL, Renner KJ, Forster GL, Tejani-Butt S (2010) Central monoamine levels differ between rat strains used in studies of depressive behavior. Brain Res 1355:41–51CrossRefPubMedPubMedCentralGoogle Scholar
  53. Sibley MH, Kuriyan AB, Evans SW, Waxmonsky JG, Smith BH (2014) Pharmacological and psychosocial treatments for adolescents with ADHD: an updated systematic review of the literature. Clin Psych Rev 34:218–232CrossRefGoogle Scholar
  54. Silva N, Szobot CM, Shih MC, Hoexter MQ, Anselmi CE, Pechansky F, Bressan RA, Rohde LA (2014) Searching for a neurobiological basis for self-medication theory in ADHD comorbid with substance use disorders: an in vivo study of dopamine transporters using (99 m)Tc-TRODAT-1 SPECT. Clin Nucl Med 39:e129–e134PubMedGoogle Scholar
  55. Solanto MV (2000) Clinical psychopharmacology of AD/HD: implications for animal models. Neurosci Biobehav Rev 24:27–30CrossRefPubMedGoogle Scholar
  56. Somkuwar SS, Darna M, Kantak KM, Dwoskin LP (2013a) Adolescence methylphenidate treatment in a rodent model of attention deficit/hyperactivity disorder: dopamine transporter function and cellular distribution in adulthood. Biochem Pharmacology 86:309–316CrossRefGoogle Scholar
  57. Somkuwar SS, Jordan CJ, Kantak KM, Dwoskin LP (2013b) Adolescent atomoxetine treatment in a rodent model of ADHD: effects on cocaine self- administration and dopamine transporters in frontostriatal regions. Neuropsychopharmacology 38:2588–2597CrossRefPubMedPubMedCentralGoogle Scholar
  58. Somkuwar SS, Kantak KM, Bardo MT, Dwoskin LP (2016) Adolescent methylphenidate treatment differentially alters adult impulsivity and hyperactivity in the spontaneously hypertensive rat model of ADHD. Pharmacol Biochem Behav 141:66–77CrossRefPubMedGoogle Scholar
  59. Spealman RD, Goldberg SR (1978) Drug self-administration by laboratory animals: control by schedules of reinforcement. Annu Rev Pharmacol Toxicol 18:313–339CrossRefPubMedGoogle Scholar
  60. Spear LP (2000) The adolescent brain and age-related behavioral manifestations. Neurosci Biobehav Rev 24:417–463CrossRefPubMedGoogle Scholar
  61. Stanis JJ, Andersen SL (2014) Reducing substance use during adolescence: a translational framework for prevention. Psychopharmacology (Berlin) 231:1437–1453CrossRefGoogle Scholar
  62. Steinhausen H-C, Bisgaard C (2014) Substance use disorders in association with attention-deficit/hyperactivity disorder, co-morbid mental disorders, and medication in a nationwide sample. Eur Neuropsychopharmacol 24:232–241CrossRefPubMedGoogle Scholar
  63. Substance Abuse and Mental Health Services Administration SAMHSA (2006) Results from the 2005 National Survey on Drug Use and Health: National findings. Office of Applied Studies, NSDUH Series H-30, DHHS Publication No. SMA 06–4194. Rockville, MDGoogle Scholar
  64. Sulzer D, Sonders MS, Poulsen NW, Galli A (2005) Mechanisms of neurotransmitter release by amphetamines: a review. Prog Neurobiol 75:406–433CrossRefPubMedGoogle Scholar
  65. Tanda G, Pontiera FE, Frau R, Chiara GD (1997) Contribution of blockade of the noradrenaline carrier to the increase of extracellular dopamine in the rat prefrontal cortex by amphetamine and cocaine. European J Neurosci 9:2077–2085CrossRefGoogle Scholar
  66. Vendruscolo LF, Izidio GS, Takahashi RN (2009) Drug reinforcement in a rat model of attention deficit/hyperactivity disorder - the spontaneously hypertensive rat (SHR). Curr Drug Abuse Rev 2:177–183CrossRefPubMedGoogle Scholar
  67. Visser SN, Danielson ML, Bitsko RH, Holbrook JR, Kogan MD, Ghandour RM, et al. (2014) Trends in the parent-report of health care provider-diagnosed and medicated attention-deficit/hyperactivity disorder: United States, 2003-2011. J Am Acad Child Adolesc Psychiatry 53:34–46e2CrossRefPubMedGoogle Scholar
  68. West CH, Bonsall RW, Emery MS, Weiss JM (1999) Rats selectively bred for high and low swim-test activity show differential responses to dopaminergic drugs. Psychopharmacology (Berlin) 146:241–251CrossRefGoogle Scholar
  69. Wilens TE, Faraone SV, Biederman J, Gunawardene S (2003) Does stimulant therapy of attention-deficit/hyperactivity disorder beget later substance abuse? A meta-analytic review of the literature. Pediatrics 111:179–185CrossRefPubMedGoogle Scholar
  70. Wilkes, MA, Spratt, EG, Cobb, SM (2015) Pediatric attention deficit hyperactivity disorder (ADHD) medication. Available at Accessed 20 Mar 2016
  71. Womersley JS, Hsieh JH, Kellaway LA, Gerhardt GA, Russell VA (2011) Maternal separation affects dopamine transporter function in the spontaneously hypertensive rat: an in vivo electrochemical study. Behav Brain Func 7:49CrossRefGoogle Scholar
  72. Xie Z, Miller GM (2009) A receptor mechanism for methamphetamine action in dopamine transporter regulation in brain. J Pharm Exper Therapeutics 330:316–325CrossRefGoogle Scholar
  73. Xie Z, Westmoreland SV, Bahn ME, Chen GL, Yang H, Vallender EJ, et al. (2007) Rhesus monkey trace amine-associated receptor 1 signaling: enhancement by monoamine transporters and attenuation by the D2 autoreceptor in vitro. J Pharm Exper Therapeutics 321:116–127CrossRefGoogle Scholar
  74. Zahniser NR, Sorkin A (2004) Rapid regulation of the dopamine transporter: role in stimulant addiction? Neuropharmacology 47:80–91CrossRefPubMedGoogle Scholar
  75. Zhang-James Y, Yang L, Middleton FA, Yang L, Patak J, Faraone SV (2014) Autism-related behavioral phenotypes in an inbred rat substrain. Behav Brain Res 269:103–114CrossRefPubMedGoogle Scholar
  76. Zimmer BA, Chiodo KA, Roberts DC (2014) Reduction of the reinforcing effectiveness of cocaine by continuous D-amphetamine treatment in rats: importance of active self- administration during treatment period. Psychopharmacology (Berlin) 231:949–954CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2016

Authors and Affiliations

  • Chloe J. Jordan
    • 1
  • Carley Lemay
    • 1
  • Linda P. Dwoskin
    • 2
  • Kathleen M. Kantak
    • 1
    Email author
  1. 1.Department of Psychological and Brain SciencesBoston UniversityBostonUSA
  2. 2.Department of Pharmaceutical Sciences, College of PharmacyUniversity of KentuckyLexingtonUSA

Personalised recommendations